Metabolic dysregulation in melanoma: cause or consequence?
Parmenter and colleagues identify molecular pathways by which BRAF-MAPK signaling regulates glycolysis in melanoma, suggesting novel approaches to target these metabolic dependencies.
Center for Melanoma, Massachusetts General Hospital Cancer Center and Cutaneous Biology Research Center, Harvard Medical School, Boston, Massachusetts.
Rizwan
R
Haq
D006019:Glycolysis / Q000187:drug effects*; D006801:Humans; D008545:Melanoma / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics*
D047428:Protein Kinase Inhibitors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf